PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023
12 7월 2023 - 5:03AM
PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a
surgical robotics company focused on advancing patient care by
developing transformative solutions in urology, today announced it
will report financial results for the second quarter of 2023 before
market open on Thursday, July 27, 2023. The Company’s management
will host a corresponding conference call beginning at 8:00 a.m.
Eastern Time.
Investors interested in listening to the conference call may do
so by following one of the below links:
- Webcast link for interested listeners:
- https://edge.media-server.com/mmc/p/fw7aiho7
- Dial-in registration for sell-side research analysts:
-
https://register.vevent.com/register/BIef004df48e304420a49f82d3ae63fa4a
Live audio of the webcast will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com. Each webcast will be available
for replay for at least 90 days after the event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 150 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@PROCEPT-BioRobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024